• Linkedin
  • Twitter
  • Youtube
  • Facebook
  • Instagram
HCS Pharma
  • Company
    • About us
    • Team
    • Scientific Advisory Board
    • Advisory Board
    • R&D programs and partnerships
      • BioPharMEMS
      • MIMLIVEROnChip
      • Nanostem
      • NEUROCELL3D
      • ONCO3D
      • RHU CHOPIN
      • ScaLABle-MEAT
      • VisuAI
    • Pressroom
      • Press releases
      • Photos for the press
      • HCS Pharma in press
    • Customer testimonials
    • Labels, prizes and distinctions
    • Partners and Memberships
    • Careers
    • Privacy Policy
  • BIOMIMESYS®
    • What is BIOMIMESYS® hydroscaffold?
    • BIOMIMESYS® Brain
    • BIOMIMESYS® Liver
    • BIOMIMESYS® Adipose tissue
    • BIOMIMESYS® Oncology
    • BIOMIMESYS® Custom
  • Support
    • BIOMIMESYS® Custom
    • Dermocosmetology
      • Anti-Aging
      • Skin Microbiota
      • Anti-oxidant
        • Oxidative stress
        • Lipid peroxidation
        • Glutathione Stock
      • Wound Healing
      • Cosmetics custom developments
    • Pharmacology
      • Parkinson
      • Alzheimer
      • Migration
      • Cell cycle arrest
  • Ressources
    • Publications
    • Application Notes
    • Conferences & Webinars
    • News
    • Posters
    • Brochures
    • BIOMIMESYS® tutorials
    • Customer testimonials
    • Certificate of Analyse
    • Protocols
    • Frequently Asked Questions
  • Contacts
    • How to contact us ?
    • Subscribe to our Newsletter

innovation

News

Agrément CIR jusqu’en 2023 pour HCS Pharma

Nous sommes heureux de vous annoncer que le Ministère de l’Enseignement Supérieur et de la Recherche a accordé à HCS Pharma l’agrément au Crédit d’Impôt Recherche (CIR) jusqu’en 2023, en regard de nos activités de R&D. For non-french readers, the CIR (Research Tax Credit) concept is explain here. Our customers can Read more…

By Elodie Vandenhaute, 2 months2 months ago
Biomimesys

Great success for BIOMIMESYS® presentation at Academia Sinica (Taiwan)

We are really proud to work on a real partnership with the team of Tokyo Future Style (TFS) Taïwan for almost a year now. Joseph Chou, member of our business advisory board and Pr John Lo, member of our scientific advisory board, have fully understood the value of BIOMIMESYS® our Read more…

By Grégory MAUBON, 7 months4 months ago
News

Meet HCS Pharma @ Nutrevent in Rennes next week!

With more than 25 countries represented, NutrEvent is THE place to be for business and innovation in Food, Nutrition and Health. It will take place next week in Rennes congress centre (Couvent des Jacobins), on the 22nd and 22rd of October. Our stand will be on Eurasanté Pavilion (Level 1 Read more…

By Elodie Vandenhaute, 2 years4 months ago
SLAS Europe Barcelona
News

We hope to see you in SLAS 2019 in Barcelona (26-27 june)?

Our CEO, Nathalie is the Chairwoman of the session “ Next Generation High-Content Bioimaging – Phenotypic Discovery” (Track 3 – session 2) at next SLAS Barcelona event. This event will bring together more than 1,000 scientists and technologists from around the world. The theme for the 2019 Europe Conference is Read more…

By Nathalie MAUBON, 2 years4 months ago
News

Interested by e-health? Join us at BPI France to be informed about the last innovations from CES 2019!

Every year, the CES (Consumer Electronics Show) in Las Vegas is the major meeting for technological innovations for consumer market. This year, many companies (more than 600) presented products and services in the healthcare domain (including medtech and wellness). It represents a 25% increase compared to 2018. Why is this Read more…

By Grégory MAUBON, 2 years4 months ago
News

HCS Pharma has joined the Cosmetic Valley

We are now in the competitiveness cluster

By Julian Bursztyka, 3 years4 months ago
HCS, HCA & Biology

Reemergence of phenotypic screening

After having been eclipsed by Target-Based Screening, Phenotypic Screening is finally shining again

By Nathalie MAUBON, 5 years4 years ago
HCS, HCA & Biology

Open innovation to sharing the risk

The pharmaceutical industry is in upheaval. Since 20 years, inefficiency of pharmaceutical industry to turn its discoveries into new drugs force them to change their model.

By Nathalie MAUBON, 5 years4 years ago
News

Meet us at Drug Discovery 2015 in Telford the 2nd & 3rd of September

We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September in Telford.

By Nathalie MAUBON, 6 years4 months ago
Clic to get more information

BIOMIMESYS®

Contacts
Contact us with this form!
Or
+33 769 999 137

Newsletter

Recent Posts
  • The importance of extracellular matrix in cancers
  • Webinar “Applications for 3D in vitro models with BIOMIMESYS® Adipose Tissue and preview of future BIOMIMESYS® Skin” (April 20 & 22)
  • Lucille joins us to develop hepatocellular models and hiPSCs-derived liver organoids
  • Our next webinar with Molecular Devices : A physiologically-relevant 3D ECM for in vitro oncology research and intelligent high-content imaging of 3D models
  • In silico drug development: a perfect supplement to our in vitro 3D BIOMIMESYS technology
We talk about …
3D 3D cell culture 3D culture BIOMIMESYS BIOMIMESYS Brain blood brain barrier brain cancer cell CHOPIN congress cosmetology dermocosmetology drug ECM ELRIG event extracellular matrix forum labo genotoxicity HCA HCS hcs pharma High content screening hyaluronic acid imaging innovation in vitro liver meeting Microbiota microenvironment microscopy model Molecular Devices NEUROCELL3D neurotoxicity oncology Parkinson phenotypic screening picture rennes screening skin toxicology
  • Company
  • BIOMIMESYS®
  • Support
  • Ressources
  • Contacts
HCS Pharma (c) 2021 | Hestia | Powered by WordPress